

# Maria Ilaria Del Principe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4290780/publications.pdf>

Version: 2024-02-01

62  
papers

3,078  
citations

186265  
28  
h-index

161849  
54  
g-index

63  
all docs

63  
docs citations

63  
times ranked

3646  
citing authors

#	ARTICLE	IF	CITATIONS
1	Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). <i>Blood</i> , 2003, 101, 2125-2131.	1.4	309
2	Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 332-341.	1.4	246
3	Clinical significance of CD38 expression in chronic lymphocytic leukemia. <i>Blood</i> , 2001, 98, 2633-2639.	1.4	242
4	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 865-873.	1.4	226
5	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	17.0	189
6	Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2006, 108, 853-861.	1.4	171
7	Toward Optimization of Postremission Therapy for Residual Disease—Positive Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 4944-4951.	1.6	165
8	Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. <i>Blood</i> , 2010, 116, 2295-2303.	1.4	126
9	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506.	2.5	106
10	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. <i>Blood Reviews</i> , 2017, 31, 17-29.	5.7	98
11	Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 2008, 112, 119-128.	4.1	86
12	Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. <i>Haematologica</i> , 2007, 92, 605-611.	3.5	76
13	Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007, 109, 2989-2998.	1.4	62
14	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, 77-85.	3.5	53
15	CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014075.	1.3	50
16	A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. <i>Journal of Cellular Physiology</i> , 2006, 207, 354-363.	4.1	49
17	The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. <i>Cancer</i> , 2005, 104, 2743-2752.	4.1	45
18	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. <i>Clinical Cancer Research</i> , 2010, 16, 620-628.	7.0	44

#	ARTICLE	IF	CITATIONS
19	A cluster of <i>Geotrichum clavatum</i> ( <i>Saprochaete clavata</i> ) infection in haematological patients: a first Italian report and review of literature. <i>Mycoses</i> , 2016, 59, 594-601.	4.0	44
20	Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. <i>American Journal of Hematology</i> , 2020, 95, 1466-1472.	4.1	42
21	Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. <i>Thrombosis Research</i> , 2013, 132, 511-514.	1.7	41
22	Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. <i>Seminars in Hematology</i> , 2018, 55, 209-214.	3.4	39
23	ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 284-292.	1.5	38
24	Thrombosis in adult patients with acute leukemia. <i>Current Opinion in Oncology</i> , 2017, 29, 448-454.	2.4	38
25	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <i>Annals of Hematology</i> , 2014, 93, 1765-1774.	1.8	34
26	P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003, 121, 730-738.	2.5	32
27	A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 628-631.	4.1	32
28	Signature of B-CLL with different prognosis by Shrunk centroids of surface antigen expression profiling. <i>Journal of Cellular Physiology</i> , 2005, 204, 113-123.	4.1	30
29	High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1509-1513.	1.8	30
30	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*. <i>British Journal of Haematology</i> , 2004, 125, 203-212.	2.5	26
31	Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. <i>American Journal of Hematology</i> , 2019, 94, 1091-1097.	4.1	25
32	Monitoring of minimal residual disease in acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2009, 21, 582-588.	2.4	24
33	Apoptosis and immaturity in acute myeloid leukemia. <i>Hematology</i> , 2005, 10, 25-34.	1.5	19
34	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. <i>Journal of Translational Medicine</i> , 2010, 8, 23.	4.4	19
35	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 95-106.	1.3	16
36	The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 149, 383-387.	2.5	15

#	ARTICLE	IF	CITATIONS
37	Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. <i>Haematologica</i> , 2022, 107, 996-999.	3.5	15
38	Clinical significance of c.7544â€“7545 del<scp>CT </scp><i><scp>NOTCH</scp>1</i> mutation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 415-418.	2.5	14
39	Applications and efficiency of flow cytometry for leukemia diagnostics. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1089-1097.	3.1	14
40	Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network. <i>Haematologica</i> , 2020, 106, 39-45.	3.5	14
41	<scp>ESCCA</scp>/<scp>ISCCA</scp> protocol for the analysis of cerebrospinal fluid by multiparametric flowâ€“cytometry in hematological malignancies. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 269-281.	1.5	13
42	Minimal residual disease as biomarker for optimal biologic dosing of <scp>ARA</scp>â€“<scp>C</scp> in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 125-131.	4.1	12
43	Multidimensional Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 445-450.	1.3	11
44	â€“Real-lifeâ€“ analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1062-1068.	3.0	11
45	Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. <i>Chemotherapy</i> , 2021, 66, 47-52.	1.6	10
46	Extensive toxic epidermal necrolysis following brentuximab vedotin administration. <i>Annals of Hematology</i> , 2015, 94, 355-356.	1.8	9
47	Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 6246.	3.7	9
48	Evaluation of the prognostic relevance of <scp>I</scp>â€“selectin and ICAM1 expression in myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2008, 80, 107-114.	2.2	7
49	Thoracic Cord Compression Caused by Epidural Extramedullary Hematopoiesis During Erythroid-Stimulating Agent Therapy in Two Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2013, 31, e189-e191.	1.6	7
50	Longitudinal detection of <i>DNMT3A</i><sup>R882H</sup> transcripts in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E120-E123.	4.1	7
51	Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEMâ€“12B study). <i>Mycoses</i> , 2020, 63, 1094-1100.	4.0	6
52	High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. <i>Journal of Fungi (Basel)</i> , 2021, 7, 1065.	1.6	5
53	Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2006, 85, 136-138.	1.8	5
54	An evaluation of enasidenib for the treatment of acute myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1935-1942.	1.8	5

#	ARTICLE	IF	CITATIONS
55	Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia. Expert Review of Anticancer Therapy, 2006, 6, 1787-1800.	2.4	4
56	Advances in the treatment of elderly and frail patients with acute myeloid leukemia. Current Opinion in Oncology, 2014, 26, 663-669.	2.4	4
57	Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016 survey. Mycoses, 2022, 65, 171-177.	4.0	3
58	Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma, 2009, 50, 857-858.	1.3	2
59	Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms. Leukemia and Lymphoma, 2022, 63, 1754-1757.	1.3	2
60	In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia. Journal of Clinical Medicine, 2022, 11, 1776.	2.4	1
61	Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia. Annals of Hematology, 2014, 93, 1611-1612.	1.8	0
62	When Viruses Meet Fungi: Tackling the Enemies in Hematology. Journal of Fungi (Basel, Switzerland), 2022, 8, 184.	3.5	0